AFAntonino de Jesus Francisco

Antonino de Jesus Francisco

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Antonino de Jesus Francisco has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Molecular subtypes and lymph-node metastasis in endometrial cancer: An updated systematic review and meta-analysis

    by Rafael Alvim Pereira, Gabriel Barcellos, Milena Tumelero, Antonino Francisco, Bianca Collin, Gabriel Valagni, Nicolas Peruzzo, Gabriel Lenz

    • 1 January 2026
      • Vol. 41  (1)
    Open Access

    Mid-term Outcomes of Transcatheter Aortic Valve Replacement vs. Surgical Aortic Valve Replacement in Low-to-Moderate Risk Patients with Severe Aortic Stenosis: A Systematic Review and Meta-analysis.

    by Capela António Dicazeco Pascoal, Hilária Saugo Faria, Antonino de Jesus Francisco, Clara de Andrade Pontual Peres, Luiz Fernando Tavares, Barbara Bombassaro Masiero, Mohamed Doma, Valdano Manuel

    Several clinical trials have demonstrated the non-inferiority of transcatheter aortic valve replacement compared with surgical aortic valve replacement in patients with severe aortic stenosis and low to intermediate surgical risk. However, mid-term results are still contentious. We performed this meta-analysis to compare the safety and efficacy of transcatheter vs. surgical aortic valve replacement in the mid-term in patients with aortic stenosis at low to moderate surgical risk. We searched Embase, PubMed®, and Cochrane databases for randomized clinical trials that compared transcatheter with surgical aortic valve replacement in patients with symptomatic severe aortic stenosis with a follow-up of at least four years. Outcomes of interest were all-cause mortality and disabling stroke. We included six randomized clinical trials encompassing 6,444 patients with severe aortic stenosis, of whom 3,282 (50.9%) underwent transcatheter aortic valve replacement. There was no difference in all-cause mortality (risk ratio [RR] 1.08; 95% confidence interval [CI] 0.94 - 1.25; P = 0.30) and disabling stroke (RR 0.95; 95% CI 0.75 - 1.21; P = 0.67) between groups. In the subgroup analysis, five-year mortality (RR 1.28; 95% CI 1.10 - 1.49) was higher in the transcatheter group. The new pacemaker implantation (RR 2.22; 95% CI 1.42 - 3.45) rate was higher in the transcatheter group. However, the new atrial fibrillation (RR 0.40; 95% CI 0.31 - 0.52) rate was higher in the surgical group. Mid-term mortality and disabling stroke rates in patients with severe aortic stenosis treated with either transcatheter or surgical aortic valve replacement were similar.